Your browser doesn't support javascript.
loading
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
Kalincik, Tomas; Kister, Ilya; Bacon, Tamar E; Malpas, Charles B; Sharmin, Sifat; Horakova, Dana; Kubala-Havrdova, Eva; Patti, Francesco; Izquierdo, Guillermo; Eichau, Sara; Ozakbas, Serkan; Onofrj, Marco; Lugaresi, Alessandra; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Grammond, Pierre; Sola, Patrizia; Ferraro, Diana; Alroughani, Raed; Terzi, Murat; Boz, Cavit; Grand'Maison, Francois; Bergamaschi, Roberto; Gerlach, Oliver; Sa, Maria J; Kappos, Ludwig; Cartechini, Elisabetta; Lechner-Scott, Jeannette; van Pesch, Vincent; Shaygannejad, Vahid; Granella, Franco; Spitaleri, Daniele; Iuliano, Gerardo; Maimone, Davide; Prevost, Julie; Soysal, Aysun; Turkoglu, Recai; Ampapa, Radek; Butzkueven, Helmut; Cutter, Gary.
Afiliación
  • Kalincik T; CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia/MS Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Kister I; Neurology, NYU School of Medicine, New York, NY, USA.
  • Bacon TE; Neurology, NYU School of Medicine, New York, NY, USA.
  • Malpas CB; CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia/MS Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Sharmin S; CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia/MS Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Horakova D; Department of Neurology, Charles University in Prague, Prague, Czech Republic.
  • Kubala-Havrdova E; Department of Neurology, Charles University in Prague, Prague, Czech Republic.
  • Patti F; GF Ingrassia Department, University of Catania, Catania, Italy.
  • Izquierdo G; Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Eichau S; Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Ozakbas S; Dokuz Eylul University, Izmir, Turkey.
  • Onofrj M; Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, Chieti, Italy.
  • Lugaresi A; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy/Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy.
  • Prat A; Universite de Montreal and CHUM, Montreal, QC, Canada.
  • Girard M; Universite de Montreal and CHUM, Montreal, QC, Canada.
  • Duquette P; Universite de Montreal and CHUM, Montreal, QC, Canada.
  • Grammond P; CISSS Chaudi're-Appalache, Levis, QC, Canada.
  • Sola P; Neurology Unit, Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy.
  • Ferraro D; Neurology Unit, Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy/Department of Biomedical, Metabolic and Neurosciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Alroughani R; Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait.
  • Terzi M; Medical Faculty, 19 Mayis University, Samsun, Turkey.
  • Boz C; KTU Medical Faculty Farabi Hospital, Trabzon, Turkey.
  • Grand'Maison F; Neuro Rive-Sud, Greenfield Park, QC, Canada.
  • Bergamaschi R; IRCCS Mondino Foundation, Pavia, Italy.
  • Gerlach O; Department of Neurology, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands/School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Sa MJ; Hospital S. João, Porto, Portugal; University Fernando Pessoa, Porto, Portugal.
  • Kappos L; Research Center for Clinical Neuroimmunology and Neuroscience(RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Cartechini E; UOC Neurologia, Azienda Sanitaria Unica Regionale Marche-AV3, Macerata, Italy.
  • Lechner-Scott J; School of Medicine and Public Health, The University of Newcastle, Newcastle, NSW, Australia.
  • van Pesch V; Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
  • Shaygannejad V; Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran.
  • Granella F; Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Spitaleri D; Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy.
  • Iuliano G; Ospedali Riuniti di Salerno, Salerno, Italy.
  • Maimone D; Neurology Unit, Piazza S. Maria di Gesù 5, Catania, Italy.
  • Prevost J; CSSS Saint-Jérôme, Saint-Jerome, QC, Canada.
  • Soysal A; Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey.
  • Turkoglu R; Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.
  • Ampapa R; Nemocnice Jihlava, Jihlava, Czech Republic.
  • Butzkueven H; Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Cutter G; Department of Biostatistics, UAB School of Public Health, Birmingham, AL, USA.
Mult Scler ; 28(11): 1752-1761, 2022 10.
Article en En | MEDLINE | ID: mdl-35373638
ABSTRACT

BACKGROUND:

The MSBase prediction model of treatment response leverages multiple demographic and clinical characteristics to estimate hazards of relapses, confirmed disability accumulation (CDA), and confirmed disability improvement (CDI). The model did not include Multiple Sclerosis Severity Score (MSSS), a disease duration-adjusted ranked score of disability.

OBJECTIVE:

To incorporate MSSS into the MSBase prediction model and compare model accuracy with and without MSSS.

METHODS:

The associations between MSSS and relapse, CDA, and CDI were evaluated with marginal proportional hazards models adjusted for three principal components representative of patients' demographic and clinical characteristics. The model fit with and without MSSS was assessed with penalized r2 and Harrell C.

RESULTS:

A total of 5866 MS patients were started on disease-modifying therapy during prospective follow-up (age 38.4 ± 10.6 years; 72% female; disease duration 8.5 ± 7.7 years). Including MSSS into the model improved the accuracy of individual prediction of relapses by 31%, of CDA by 23%, and of CDI by 24% (Harrell C) and increased the amount of variance explained for relapses by 49%, for CDI by 11%, and for CDA by 10% as compared with the original model.

CONCLUSION:

Addition of a single, readily available metric, MSSS, to the comprehensive MSBase prediction model considerably improved the individual accuracy of prognostics in MS.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Esclerosis Múltiple Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Esclerosis Múltiple Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Australia